Clinical Trials

Date: 2017-08-03

Type of information: Publication of results in a medical journal

phase:

Announcement:

Company:

Product:

Action mechanism:

Disease: refractory aggressive non-Hodgkin lymphoma (NHL)

Therapeutic area: Cancer - Oncology

Country:

Trial details: SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research),

Latest news:

• • On August 3, 2017, Kite Pharma announced the publication of the first large-scale multi-institutional analysis of outcomes of patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the latest electronic edition of Blood ((Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017 :blood-2017-03-769620; doi: https://doi.org/10.1182/blood-2017-03-769620). 
• The study, SCHOLAR-1 (Retrospective Non-Hodgkin Lymphoma Research), showed outcomes in patients with refractory aggressive NHL subtypes including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) or primary mediastinal B-cell lymphoma (PMBCL) following treatment with currently available therapies: - Objective response rate of 26 percent - Complete response rate of 7 percent - Median overall survival of 6.3 months
• These findings highlight the unmet medical need and provide an important benchmark for studies that address this refractory patient population.
• SCHOLAR-1 uses pooled, patient-level data from two of the largest randomized controlled studies in NHL, the Canadian Cancer Trials Group study Ly.12 and the Lymphoma Academic Research Organization (LYSARC) Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study, and from two observational cohorts from MD Anderson Cancer Center and the Molecular Epidemiology Resource of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (IA/MC). The analysis includes 636 patients who met criteria for refractory DLBCL, TFL and PMBCL. Refractory status was defined as progressive disease or stable disease as best response to last chemotherapy, or relapse ?12 months post-ASCT. While patients with relapsed/refractory NHL, a more broadly defined patient population studied in Ly.12 and CORAL, have heterogeneous outcomes to subsequent therapy, the subgroup of patients with strictly refractory NHL, as studied in SCHOLAR-1, have uniformly poor outcomes and greater unmet need. In the refractory NHL patient pool studied in SCHOLAR-1, objective response rate was 26 percent, complete response rate was 7 percent, and median overall survival was 6.3 months. Outcomes for the refractory NHL patient pool studied in SCHOLAR-1 were consistently poor across patient subgroups. SCHOLAR-1 was funded through an unrestricted grant from Kite.

Is general: Yes